標(biāo)題: Titlebook: Drug Delivery to the Brain; Physiological Concep Margareta Hammarlund-Udenaes,Elizabeth C.M. de Lan Book 20141st edition American Associati [打印本頁(yè)] 作者: 撕成碎片 時(shí)間: 2025-3-21 19:46
書目名稱Drug Delivery to the Brain影響因子(影響力)
書目名稱Drug Delivery to the Brain影響因子(影響力)學(xué)科排名
書目名稱Drug Delivery to the Brain網(wǎng)絡(luò)公開度
書目名稱Drug Delivery to the Brain網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Drug Delivery to the Brain被引頻次
書目名稱Drug Delivery to the Brain被引頻次學(xué)科排名
書目名稱Drug Delivery to the Brain年度引用
書目名稱Drug Delivery to the Brain年度引用學(xué)科排名
書目名稱Drug Delivery to the Brain讀者反饋
書目名稱Drug Delivery to the Brain讀者反饋學(xué)科排名
作者: Tracheotomy 時(shí)間: 2025-3-21 22:38
978-1-4939-4366-1American Association of Pharmaceutical Scientists 2014作者: Bone-Scan 時(shí)間: 2025-3-22 03:19
Sexuelle Selektion: evolution?re Grundlagens differences, in vitro/in vivo differences, age-related differences, and normal/disease differences, and these need to be understood in order to guide rational drug discovery and development. To address this issue, we have developed an absolute quantification method of protein expression, called qu作者: 夾死提手勢(shì) 時(shí)間: 2025-3-22 05:45
Methoden und Konzepte der Verhaltensbiologie While the liver is the main site of drug metabolism, drug-metabolizing enzymes that catalyze functionalization and conjugation reactions have been detected in the brain, and several of these enzymes are notably enriched at blood–brain interfaces. This chapter summarizes the principles of drug metab作者: 咒語(yǔ) 時(shí)間: 2025-3-22 09:33 作者: 迎合 時(shí)間: 2025-3-22 14:04 作者: 迎合 時(shí)間: 2025-3-22 20:22 作者: CAMP 時(shí)間: 2025-3-23 00:26 作者: cauda-equina 時(shí)間: 2025-3-23 03:25
,General Remarks – Allgemeine Hinweise,riers (BCSFB) that separate the blood from brain interstitial and cerebrospinal fluids, respectively. New strategies to circumvent the BBB are greatly needed to utilize polar pharmaceuticals and large biotherapeutics for CNS disease treatment because the BBB is typically impermeable to such compound作者: 極微小 時(shí)間: 2025-3-23 08:26 作者: Intervention 時(shí)間: 2025-3-23 10:17 作者: Alopecia-Areata 時(shí)間: 2025-3-23 15:39 作者: conformity 時(shí)間: 2025-3-23 18:22
Drug Delivery to the Brain978-1-4614-9105-7Series ISSN 2210-7371 Series E-ISSN 2210-738X 作者: BAIL 時(shí)間: 2025-3-24 02:13 作者: Urea508 時(shí)間: 2025-3-24 05:58 作者: AGGER 時(shí)間: 2025-3-24 07:40
Drug Metabolism at the Blood–Brain and Blood–CSF Barriersolism, reviews the molecular and functional evidence for drug-metabolizing enzyme location at both the blood–brain barrier (BBB) and blood–CSF barrier (BCSFB), and discusses their functional significance for modulating cerebral drug delivery and brain toxin exposure.作者: Torrid 時(shí)間: 2025-3-24 12:12
Book 20141st editionarriers, the most important being the blood –brain barrier (BBB). Many factors are therefore critical to consider for CNS drug delivery, e.g. active/passive transport across the BBB, intra-brain distribution, and central/systemic pharmacokinetics, to name a few.?Neurological disease and trauma condi作者: 善于 時(shí)間: 2025-3-24 17:50
,General Remarks – Allgemeine Hinweise,we will highlight the issues that should be considered when translating basic research towards clinical development. Although it is still unrealistic to expect a magic bullet for exclusive CNS drug delivery, much progress has been made towards successful development of novel treatments for patients with devastating brain diseases.作者: Insulin 時(shí)間: 2025-3-24 22:41 作者: 因無(wú)茶而冷淡 時(shí)間: 2025-3-24 23:28 作者: fulcrum 時(shí)間: 2025-3-25 07:15 作者: sperse 時(shí)間: 2025-3-25 11:26
Drug Discovery Methods for Studying Brain Drug Delivery and Distribution., equilibrium dialysis-based brain homogenate and brain slice methods, are described. The assessment of extent of BBB transport and intracellular distribution of NCEs, the identification of intra-brain distribution patterns, and their integration with pharmacodynamic measurements are valuable imple作者: membrane 時(shí)間: 2025-3-25 13:44
Prediction of Drug Exposure in the Brain from the Chemical Structuren, but also indicated no dependence on lipophilicity. The challenges associated with obtaining high predictivity models for K. confirm the contemporary view of the blood–brain barrier (BBB) as not only being physical and passive in nature but also involving specific carrier-mediated processes. It fo作者: Cardiac-Output 時(shí)間: 2025-3-25 17:12
Pharmacoeconomic Considerations in CNS Drug Developmentthe commercial aspects of the technology and the requirements attached to the funding mechanisms for clinical development. Early choices about delivery modality and target therapy (indication) have important consequences for the development process. An understanding of the forces that currently driv作者: 制定法律 時(shí)間: 2025-3-25 20:35
Intranasal Drug Delivery to the Brainbutes of the nasal mucosa and its associated cranial nerves that allow small but significant fractions of certain intranasally applied drugs to transfer across the nasal epithelia and subsequently be transported directly into the CNS. We also review the preclinical and clinical literature related to作者: NIB 時(shí)間: 2025-3-26 00:46
Book 20141st edition affect drug action. This book describes small and large drug delivery to the brain with an emphasis on the physiology of the BBB and the principles and concepts for drug delivery across the BBB and distribution within the brain. It contains methods descriptions for studying drug delivery, routes an作者: 柔軟 時(shí)間: 2025-3-26 05:33 作者: 聯(lián)邦 時(shí)間: 2025-3-26 11:50 作者: 音樂戲劇 時(shí)間: 2025-3-26 15:05 作者: Debark 時(shí)間: 2025-3-26 18:39
https://doi.org/10.1007/978-3-662-62050-2n, but also indicated no dependence on lipophilicity. The challenges associated with obtaining high predictivity models for K. confirm the contemporary view of the blood–brain barrier (BBB) as not only being physical and passive in nature but also involving specific carrier-mediated processes. It fo作者: 真 時(shí)間: 2025-3-27 00:56
,General Remarks – Allgemeine Hinweise,the commercial aspects of the technology and the requirements attached to the funding mechanisms for clinical development. Early choices about delivery modality and target therapy (indication) have important consequences for the development process. An understanding of the forces that currently driv作者: craven 時(shí)間: 2025-3-27 04:34 作者: 杠桿 時(shí)間: 2025-3-27 08:44
2210-7371 n emphasis on the physiology of the BBB and the principles and concepts for drug delivery across the BBB and distribution within the brain. It contains methods descriptions for studying drug delivery, routes an978-1-4939-4366-1978-1-4614-9105-7Series ISSN 2210-7371 Series E-ISSN 2210-738X 作者: Ibd810 時(shí)間: 2025-3-27 11:49 作者: connoisseur 時(shí)間: 2025-3-27 17:37
Recent Progress in Blood–Brain Barrier and Blood–CSF Barrier Transport Research: Pharmaceutical Rele作者: 或者發(fā)神韻 時(shí)間: 2025-3-27 21:49 作者: 癡呆 時(shí)間: 2025-3-27 21:59
PKPD Aspects of Brain Drug Delivery in a Translational Perspective作者: 原告 時(shí)間: 2025-3-28 03:23
Integrated Approach to Optimizing CNS Penetration in Drug Discovery: From the Old to the New Paradig作者: 使厭惡 時(shí)間: 2025-3-28 09:15
Blood–Brain Barrier (BBB) Pharmacoproteomics: A New Research Field Opened Up by Quantitative Targetes differences, in vitro/in vivo differences, age-related differences, and normal/disease differences, and these need to be understood in order to guide rational drug discovery and development. To address this issue, we have developed an absolute quantification method of protein expression, called qu作者: adequate-intake 時(shí)間: 2025-3-28 13:48 作者: 肥料 時(shí)間: 2025-3-28 17:31 作者: 保守 時(shí)間: 2025-3-28 19:32
Drug Discovery Methods for Studying Brain Drug Delivery and Distributionre is now more focus on measuring or estimating target unbound drug concentrations in the brain and evaluating the quantitative aspects of drug transport across the blood–brain barrier (BBB). The techniques for investigation of the rate and extent of BBB transport of new chemical entities (NCEs) are作者: fibula 時(shí)間: 2025-3-29 02:41 作者: 名字的誤用 時(shí)間: 2025-3-29 06:09 作者: 顛簸地移動(dòng) 時(shí)間: 2025-3-29 08:29
Intranasal Drug Delivery to the Brainriers (BCSFB) that separate the blood from brain interstitial and cerebrospinal fluids, respectively. New strategies to circumvent the BBB are greatly needed to utilize polar pharmaceuticals and large biotherapeutics for CNS disease treatment because the BBB is typically impermeable to such compound作者: NATAL 時(shí)間: 2025-3-29 13:36 作者: myriad 時(shí)間: 2025-3-29 15:41
8樓作者: 苦澀 時(shí)間: 2025-3-29 20:16
9樓作者: 防止 時(shí)間: 2025-3-30 00:42
9樓作者: 柳樹；枯黃 時(shí)間: 2025-3-30 04:35
9樓作者: subordinate 時(shí)間: 2025-3-30 11:20
9樓作者: 脆弱吧 時(shí)間: 2025-3-30 15:36
10樓作者: CT-angiography 時(shí)間: 2025-3-30 19:24
10樓作者: Ambulatory 時(shí)間: 2025-3-30 22:10
10樓作者: indoctrinate 時(shí)間: 2025-3-31 02:01
10樓
